Latest GABAA receptor Stories

Addex Pharmaceuticals (SWISS: ADXN) announced today that on September 25, 2008, S.R. One Ltd, the investment arm of GlaxoSmithKline plc, has informed of reaching the threshold of 3.0% in the shareholding of Addex Pharmaceuticals Ltd., holding a total of 175,951 registered shares, corresponding to 3.0% of the voting rights. About Addex Addex Pharmaceuticals discovers and develops allosteric modulators for human health. Allosteric modulators are an emerging class of orally available small...

Addex Pharmaceuticals (SWISS: ADXN) announced today that on September 25, 2008, S.R. One Ltd, the investment arm of GlaxoSmithKline plc, has informed of reaching the threshold of 3.0% in the shareholding of Addex Pharmaceuticals Ltd., holding a total of 175,951 registered shares, corresponding to 3.0% of the voting rights. About Addex Addex Pharmaceuticals discovers and develops allosteric modulators for human health. Allosteric modulators are an emerging class of orally...

Research and Markets (http://www.researchandmarkets.com/reports/c78985) has announced the addition of Pipeline Report - Neuronal Alpha 7 Nicotinic Receptors: Candidates for the Treatment of Alzheimers Disease and Schizophrenia to their offering. Neuronal alpha 7 nicotinic receptor (a7nAChR) ligands represent an emerging class of drug for the treatment of various CNS disorders associated with cognitive dysfunction. This report describes the proof of concept supporting the development of this...